Meeting
2016 ASCO Annual Meeting
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
Authors
Biljana Bazdar-Vinovrski
Merrimack, Cambridge, MA
Biljana Bazdar-Vinovrski , Marisa Wainszelbaum , Gavin MacBeath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Clinical Trial Registration Number
NCT02538627
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS11619)
DOI
10.1200/JCO.2016.34.15_suppl.TPS11619
Abstract #
TPS11619
Poster Bd #
313b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to dabrafenib or trametinib.
First Author: Amir Noeparast
Poster
2023 ASCO Annual Meeting
Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.
First Author: Kyle Begovich
Poster
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
First Author: Sanne Huijberts
Poster
2018 Gastrointestinal Cancers Symposium
Molecular rationale for ERK and EGFR inhibition in colorectal cancer.
First Author: Timothy Joseph Yeatman